Unknown

Dataset Information

0

Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans.


ABSTRACT: Context:Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited. Objective:To investigate if IL-6 regulates bone remodeling in humans. Design:Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies. Participants:Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3. Interventions:Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6. Main outcomes measures:Effect of IL-6 on CTX levels. Results:CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3). Conclusions:IL-6 may not regulate bone remodeling in humans.

SUBMITTER: Lehrskov LL 

PROVIDER: S-EPMC7414920 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Context</h4>Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.<h4>Objective</h4>To investigate if IL-6 regulates bone remodeling in humans.<h4>Design</h4>Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT)  ...[more]

Similar Datasets

| S-EPMC8517119 | biostudies-literature
| S-EPMC6820456 | biostudies-literature
| S-EPMC4767867 | biostudies-literature
| S-EPMC5006645 | biostudies-literature
| S-EPMC5873876 | biostudies-literature
| S-EPMC11254843 | biostudies-literature
| S-EPMC7801485 | biostudies-literature
| S-EPMC4371963 | biostudies-literature
2015-04-01 | E-GEOD-45656 | biostudies-arrayexpress
| S-EPMC9837181 | biostudies-literature